Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 20, 2017— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death —
NEWTON, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported a successful outcome from the Phase 2 portion...
-
Sep 12, 2017— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies —
NEWTON, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Michael Falvey as...
-
Sep 8, 2017Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers
NEWTON, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...